WEBULL
WebtradeDownload

Thermo Fisher Scientific (TMO) Lands In Two Fast Growing Research Markets Investors Missed

Simply Wall St · 2d ago
  • Thermo Fisher Scientific (NYSE:TMO) is highlighted as a key supplier to organoid intelligence and brain organoid research tools.
  • The company is also cited as a major equipment and consumables provider across multiomics workflows, including spatial omics platforms.
  • Organoid intelligence and multiomics are gaining attention for roles in advanced research, precision medicine, and biological computing applications.
  • This focus on Thermo Fisher's role in organoid intelligence and multiomics only captures one part of the investment story. Take a look at 1 warning sign we have identified for Thermo Fisher Scientific.

For readers exploring more ways to participate in the build out of advanced research and computing infrastructure, start with 89 AI infrastructure stocks.

NYSE:TMO Earnings & Revenue Growth as at Sep 2026
NYSE:TMO Earnings & Revenue Growth as at Sep 2026

Thermo Fisher Scientific operates as a large life sciences supplier, providing instruments, consumables, diagnostics, and lab services that researchers use across fields such as organoid intelligence and multiomics. Its role as a broad tool provider gives it exposure to multiple research trends rather than a single end market.

3 things going right for Thermo Fisher Scientific that this headline doesn't cover.

What Thermo Fisher’s organoid and multiomics role really signals for the Narrative

For Thermo Fisher Scientific, being flagged as a key supplier to organoid intelligence and multiomics reinforces the Narrative’s core bull case that high impact analytical tools and broad life sciences workflows can feed recurring demand across many research areas rather than a single product cycle. The Multiskan Ease launch fits that story as a workhorse instrument for routine assays, while organoid and spatial omics exposure speaks to the catalyst around pharma and biotech customers deepening their integration with Thermo Fisher’s platform. On the bear side, this update does not address pressure points like China, academic funding or reliance on cost programs, so those Narrative risks remain intact.

See how these catalysts shape Thermo Fisher Scientific's path to a $631 fair value.

The practical checkpoint for investors is Thermo Fisher Scientific’s upcoming earnings updates through 2027, especially any quantified commentary on organoid intelligence, spatial omics and multiomics related consumables and instrument demand within Life Sciences Solutions and Analytical Instruments segments.

Thermo Fisher’s forecasts point to a destination this article has not touched

Everything here has focused on what Thermo Fisher Scientific is doing today, while the multi year projections sketch a very different picture of where this business could land. See where analysts expect Thermo Fisher Scientific to be in a few years.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.